PT-141 (Bremelanotide) vs Triptorelin

PT-141 (Bremelanotide): FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Typical dose 1000-2000 mcg. Triptorelin: Long-acting GnRH agonist — FDA-approved for prostate cancer and used in PCT protocols. Typical dose 100-200 (single PCT dose) mcg. Both fall under the Sexual Health category.

Stacking PT-141 (Bremelanotide) with Triptorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

PT-141 (Bremelanotide) is typically dosed: As needed, at least 45 minutes before activity for HSDD treatment (FDA-approved dose); As needed, 45-60 minutes before activity for General sexual function enhancement. Triptorelin is typically dosed: Single dose at cycle end (SubQ) for Post-cycle therapy (off-label single dose); Monthly / quarterly / semi-annual depot IM for Prostate cancer (clinical, depot); Monthly for Endometriosis (clinical, depot).

PT-141 (Bremelanotide): FDA approved. Bremelanotide (Vyleesi) was approved in June 2019 for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Triptorelin: FDA approved (Trelstar) for advanced prostate cancer. Other indications approved internationally (Decapeptyl, Diphereline).